Nivelles, Belgium, September 22, 2022 – Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable advanced therapy production, announces today the launch of the scale-X™ cell collect module. This new product aims to support the inoculation step for large-scale bioreactors leveraging the principles of automation and intensification.
Inoculating large-scale bioreactors requires multiple cell expansion steps, typically performed in plastic flatware. This process incurs significant costs, a substantial footprint, and an increased risk of operator-related errors. The scale-X cell collect module has been designed to overcome these challenges, resulting in a reduced aseptic risk, and a decrease in costs, footprint, and operational time, coupled with high reproducibility.
“Traditional 2D cell expansion technologies such as multilayer vessels are extremely laborious and require large footprints leading to high costs. Handling multilayer vessels becomes even more challenging when these are used to inoculate large-scale bioreactors growing trillions of cells” said CTO, Tania Pereira Chilima. “With the scale-X cell collect system, we have found a new way to automate and streamline small- to large-scale, GMP-compliant processes, and to optimize equipment, media, reagent, and labor costs. The cells are grown in a single benchtop fixed-bed bioreactor, harvested through a combination of vibration and enzymatic cleavage, and are transferred to a large-scale bioreactor within a closed system.”
“The goal was to drastically decrease risk of failure and contamination as well as reducing process volumes, while increasing product yields,” said Florence Vicaire, new CCO at Univercells Technologies. “The new scale-X cell collect module achieves those goals and represents another building block in our portfolio of tailored solutions the bioprocess industry can count on to efficiently commercialize advanced therapy processes.”
The scale-X cell collect system is an add-on harvest module for the scale-X carbo bioreactor and will be available for commercial use in Q1 2023.
Interested parties are invited to email the team and download this paper on the use of the scale-X bioreactor for scalable seed train intensification and automation.
- BPI Boston, MA from 27 to 30 September (Gamma Biosciences booth #901)
- ESGCT Edinburgh, UK from 11 to 14 October (booth #60)
- Cell & Gene Meeting on the Mesa, Carlsbad, CA from 11 to 13 October
- Webinar on the new scale-X cell collect module will be held in November
About Univercells Technologies
Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective advanced therapies production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow.
Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 following its carve-out from Univercells with the support of the Univercells Group and Gamma Biosciences.
LinkedIn: Univercells Technologies